Lutris Pharma Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Lutris Pharma's estimated annual revenue is currently $775k per year.(i)
  • Lutris Pharma's estimated revenue per employee is $155,000

Employee Data

  • Lutris Pharma has 5 Employees.(i)
  • Lutris Pharma grew their employee count by 0% last year.

Lutris Pharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.8M18-10%$43MN/A
#2
$0.8M50%N/AN/A
#3
$6M395%$23.4MN/A
#4
$8.1M5227%$12.5MN/A
#5
$1.6M100%N/AN/A
#6
$3.6M235%$8.44MN/A
#7
$5.3M340%N/AN/A
#8
$2.8M1838%$6.1MN/A
#9
$9.3M6040%$22MN/A
#10
$5.3M2856%N/AN/A
Add Company

What Is Lutris Pharma?

Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis.

keywords:N/A

N/A

Total Funding

5

Number of Employees

$775k

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M5-44%N/A
#2
$0.4M50%N/A
#3
$1.3M5-17%N/A
#4
$0.6M5-29%N/A
#5
$0.7M567%N/A